Title / AuthorYear
Human papillomavirus–associated cancers—United States, 2008–2012
LJ Viens, SJ Henley, M Watson, LE Markowitz, CC Thomas, ...
Morbidity and Mortality Weekly Report 65 (26), 661-666
2016
Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis
L Bruni, M Diaz, L Barrionuevo-Rosas, R Herrero, F Bray, FX Bosch, ...
The Lancet Global Health 4 (7), e453-e463
2016
Malaria surveillance—United States, 2015
KE Mace, PM Arguin, KR Tan
MMWR Surveillance Summaries 67 (7), 1
2018
Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience
SM Garland, SK Kjaer, N Muñoz, SL Block, DR Brown, MJ DiNubile, ...
Reviews of Infectious Diseases 63 (4), 519-527
2016
Prevalence of HPV after introduction of the vaccination program in the United States
LE Markowitz, G Liu, S Hariri, M Steinau, EF Dunne, ER Unger
Pediatrics 137 (3)
2016
Carcinogenic human papillomavirus infection
M Schiffman, J Doorbar, N Wentzensen, S De Sanjosé, C Fakhry, ...
Nature reviews Disease primers 2 (1), 1-20
2016
Human papillomaviruses; epithelial tropisms, and the development of neoplasia
N Egawa, K Egawa, H Griffin, J Doorbar
Viruses 7 (7), 3863-3890
2015
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors
M Arbyn, L Xu, C Simoens, PPL Martin‐Hirsch
Cochrane database of systematic reviews
2018
Cancer of the cervix uteri
N Bhatla, D Aoki, DN Sharma, R Sankaranarayanan
International Journal of Gynecology & Obstetrics 143, 22-36
2018
HPV vaccines–a review of the first decade
DM Harper, LR DeMars
Gynecologic oncology 146 (1), 196-204
2017
Cervical cancer
PA Cohen, A Jhingran, A Oaknin, L Denny
The Lancet 393 (10167), 169-182
2019
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
WK Huh, EA Joura, AR Giuliano, OE Iversen, RP de Andrade, KA Ault, ...
The Lancet 390 (10108), 2143-2159
2017
Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches
Z Apalla, D Nashan, RB Weller, X Castellsagué
Dermatology and therapy 7 (1), 5-19
2017
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models
M Brisson, É Bénard, M Drolet, JA Bogaards, I Baussano, S Vänskä, M Jit, ...
The Lancet Public Health 1 (1), e8-e17
2016
Epidemiology and burden of HPV-related disease
B Serrano, M Brotons, FX Bosch, L Bruni
Best practice & research Clinical obstetrics & gynaecology 47, 14-26
2018
Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study
K Kavanagh, KG Pollock, K Cuschieri, T Palmer, RL Cameron, C Watt, ...
The Lancet Infectious Diseases 17 (12), 1293-1302
2017
HPV-FASTER: broadening the scope for prevention of HPV-related cancer
FX Bosch, C Robles, M Díaz, M Arbyn, I Baussano, C Clavel, G Ronco, ...
Nature reviews Clinical oncology 13 (2), 119
2016
Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries
L Denny, S de Sanjose, M Mutebi, BO Anderson, J Kim, J Jeronimo, ...
The Lancet 389 (10071), 861-870
2017
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
M Drolet, É Bénard, N Pérez, M Brisson, H Ali, MC Boily, V Baldo, ...
The Lancet 394 (10197), 497-509
2019
Prophylactic HPV vaccination: past, present, and future
PE Castle, M Maza
Epidemiology & Infection 144 (3), 449-468
2016
1 - 20
Dates and citation counts are estimated and are determined automatically by a computer program.